European Commission Cracks Down on Delayed Generics

Source: PharmaManufacturing.com

Jun 20, 2013

The New York Times

The European Commission found that Danish pharmaceutical company Lundbeck had worked with companies such as Ranbaxy and Merck to delay market entry od less expensive generic versions of their antidepressant drug, citalopram. The case mirrors a decision made earlier this week by the United States Supreme Court regarding "pay-for-delay" tactics. Read the full story. 
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments